In particular, elevated pretreatment levels of circulating CD4+CCR9+ and CD4+CCR10+ T cells have been associated with significantly poorer overall survival in patients with advanced lung cancer undergoing anti-PD-1 immune checkpoint inhibitor (ICI) therapy. The gene discussed is CD4; the disease is lung carcinoma.